NCT01105767 is a NA clinical trial of Chlorhexidine gluconate in Staphylococcus Aureus, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.

Who is sponsoring NCT01105767?

NCT01105767 is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.

What drugs are being tested in NCT01105767?

Interventions in NCT01105767: Chlorhexidine gluconate, Supplemental training, education and hygiene.

What condition does NCT01105767 study?

NCT01105767 studies Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections.

Is NCT01105767 still recruiting?

NCT01105767 is currently completed. Last updated 1 February 2023.

Are results published for NCT01105767?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-01 · How we verify

NCT01105767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees

Completed NA Results posted Last updated 1 February 2023

What this trial tests

NA trial testing Chlorhexidine gluconate in Staphylococcus Aureus in 30,209 participants. Completed in 1 January 2012.

Timeline

1 May 2010

Primary endpoint
1 January 2012

1 January 2012

Quick facts

Lead sponsor	Henry M. Jackson Foundation for the Advancement of Military Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	prevention
Enrollment	30,209
Start date	1 May 2010
Primary completion	1 January 2012
Estimated completion	1 January 2012
Sites	1 location across United States

Drugs / interventions tested

Chlorhexidine gluconate — full drug profile →
Supplemental training, education and hygiene

Conditions studied

Staphylococcus Aureus — all drugs for Staphylococcus Aureus →
MRSA Skin Infections — all drugs for MRSA Skin Infections →
Staphylococcal Skin Infections — all drugs for Staphylococcal Skin Infections →

Sponsor

Henry M. Jackson Foundation for the Advancement of Military Medicine

Who can join

Adults 18 to 42, male only, with Staphylococcus Aureus or MRSA Skin Infections. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of Skin and Soft Tissue Infection (SSTI)
Time frame: At the end of the 20 month study
Incidence of Methicillin-resistant Staphylococcus Aureus (MRSA)-Associated SSTI
Time frame: At the end of the 20 month study

Sponsor's own description

This cluster-randomized prospective study will evaluate the effect of hygiene-based intervention strategies on the incidence of overall SSTI and MRSA-associated SSTI among military trainees. The proposed interventions used singly or in combination include standardized training and education, and weekly chlorhexidine showers.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Hygiene strategies to prevent methicillin-resistant Staphylococcus aureus skin and soft tissue infections: a cluster-randomized controlled trial among high-risk military trainees.
Ellis MW, Schlett CD, Millar EV, Wilkins KJ, et al · · 2014 · cited 39× · PMID 24633684 · DOI 10.1093/cid/ciu166
Prevalence of nasal colonization and strain concordance in patients with community-associated Staphylococcus aureus skin and soft-tissue infections.
Ellis MW, Schlett CD, Millar EV, Crawford KB, et al · · 2014 · cited 23× · PMID 25203178 · DOI 10.1086/678060
Bacterial Etiology and Risk Factors Associated with Cellulitis and Purulent Skin Abscesses in Military Trainees.
Johnson RC, Ellis MW, Schlett CD, Millar EV, et al · · 2016 · cited 16× · PMID 27780238 · DOI 10.1371/journal.pone.0165491
Frequent use of chlorhexidine-based body wash associated with a reduction in methicillin-resistant Staphylococcus aureus nasal colonization among military trainees.
Millar EV, Chen WJ, Schlett CD, Cui T, et al · · 2015 · cited 12× · PMID 25421482 · DOI 10.1128/aac.03993-14
Reduction in Acute Respiratory Infection Among Military Trainees: Secondary Effects of a Hygiene-Based Cluster-Randomized Trial for Skin and Soft-Tissue Infection Prevention.
Millar EV, Schlett CD, Law NN, Chen WJ, et al · · 2016 · cited 4× · PMID 27387422 · DOI 10.1017/ice.2016.154
Reduction in acute gastroenteritis among military trainees: secondary effects of a hygiene-based cluster-randomized trial for skin and soft tissue infection prevention.
D'Onofrio MJ, Schlett CD, Millar EV, Cui T, et al · · 2015 · cited 1× · PMID 25695181 · DOI 10.1017/ice.2014.65

Verify or expand the search:

Other trials of Chlorhexidine gluconate

Trials testing the same drug.

NCT06733506 — A Pilot Study to Evaluate Skin Swabbing With Chlorhexidine to Prevent Skin And Soft Tissue Infections Among People Who I · Phase 4 · completed
NCT02943759 — Resolution of Pain and Swelling After the Use of Neem Leaf Extract Compared to Chlorhexidine Gluconate as an Intracanal · Phase 2, PHASE3 · completed
NCT02216227 — Checklist to Prevent MRSA Surgical Site Infections · NA · completed

Other recruiting trials for Staphylococcus Aureus

Currently open trials in the same condition.

NCT06633588 — Decolonization Efficacy of Polyhexanide vs. Mupirocin · Phase 4 · recruiting
NCT06749457 — A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Dis · Phase 1, PHASE2 · recruiting
NCT06283355 — Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome · Phase 1 · recruiting
NCT06290557 — First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133 · Phase 1 · recruiting
NCT05695196 — Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant · Phase 1 · active not recruiting

Other Henry M. Jackson Foundation for the Advancement of Military Medicine trials

Trials by the same sponsor.

NCT07223684 — TDAP in Burn Patients (Group 2) · not yet recruiting
NCT07249762 — Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robu · not yet recruiting
NCT06921707 — Pilot Trial for WounDx™ Clinical Decision Support Tool · NA · recruiting
NCT06885554 — Adjustment Disorders in the US Military: Disease Trajectories and ADNM-20-Mil Validation · NA · recruiting
NCT06855186 — Symptom-Targeted Approach to Rehabilitation for Concussion (STAR-C) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01105767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henry M. Jackson Foundation for the Advancement of Military Medicine
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01105767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing